Showing 4901-4910 of 5623 results for "".
- NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to US Health Care Professionalshttps://modernod.com/news/novabay-pharmaceuticals-signs-agreement-to-distribute-covid-19-antibody-rapid-point-of-care-test-to-u-s-healthcare-professionals/2477616/NovaBay Pharmaceuticals announced an agreement with Shenzhen Microprofit Biotech to become the exclusive US distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19, according to a company news release. The fluoreca
- The Tests That Could Reopen the Country: How They Workhttps://modernod.com/news/the-tests-that-could-reopen-the-country-how-they-work/2477614/After weeks of sheltering in place, Americans are asking how soon we can return to a more normal life outside our homes. Much of the answer might be in a test. The first phase of testing has been about determining who has COVID-19. The next phase will be about who had it – or may
- How Does Coronavirus Kill? Clinicians Trace a Ferocious Rampage Through the Bodyhttps://modernod.com/news/how-does-coronavirus-kill-clinicians-trace-a-ferocious-rampage-through-the-body/2477615/As the number of confirmed cases of COVID-19 surges past 2.2 million globally and deaths surpass 150,000, clinicians and pathologists are struggling to understand the damage wrought by the coronavirus as it tears through the body. They are realizing that although the lungs are ground zero, its re
- Haag-Streit Group Acquires Majority Stake in VRmagichttps://modernod.com/news/haag-streit-group-acquires-majority-stake-in-vrmagic/2477610/In an effort to expand medical training for ophthalmologists, Haag-Streit announced that it has acquired a majority stake in VRmagic. VRmagic was established in 2001 and is a pioneer for virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit
- FDA Grants Priority Review Approval For Regeneron’s REGN-EB3 to Treat Ebolahttps://modernod.com/news/fda-crants-for-priority-review-approval-for-regenerons-regn-eb3-to-treat-ebola/2477599/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review a new biologics license application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020.
- Small Business Rescue Loan Program Is Now Out of Moneyhttps://modernod.com/news/small-business-rescue-loan-program-is-now-out-of-money/2477598/The Small Business Administration’s rescue loan program hit its $349 billion limit on Thursday and is now out of money as the nation’s top Republicans and Democrats struggle to agree on how to restore its funds, according to a CNBC
- New COVID-19 Clinical Trial Supported by Octapharma USAhttps://modernod.com/news/new-covid-19-clinical-trial-supported-by-octapharma-usa/2477593/Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator depen
- Nidek Launches the CP-9 Chart Projectorhttps://modernod.com/news/nidek-launches-the-cp-9-chart-projector/2477580/Nidek has announced the launch of the CP-9 Chart Projector, designed to provide a brighter and clearer chart display with a white LED. The long-life light source achieves high cost efficiency for daily examination, a
- Aldeyra Therapeutics Announces Potential of ADX-629 to Treat COVID-19 Patientshttps://modernod.com/news/aldeyra-therapeutics-announces-potential-of-adx-629-to-treat-covid-19-patients/2477578/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, plans to facilitate the clinical testing of its drug candidate ADX-629 in patients with COVID-19-associated respiratory compromise. The company has requested a pre-investigational new drug m
- AstraZeneca to Study BTK Inhibitor Calquence as Treatment for Cytokine Storm Associated With COVID-19 Infectionhttps://modernod.com/news/astrazeneca-to-study-btk-inhibitor-calquence-as-treatment-for-cytokine-storm-associated-with-covid-19-infection/2477575/AstraZeneca announced that it will investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of the cytokine storm associated with COVID-19 infection in severely ill patients. The company noted that the design of the CALAVI study is based on “strong scientifi